impact factor

Case Reports


Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature

1, 2


  1. Division of Rheumatology, University of Utah, Salt Lake Veterans Affair Medical Center, Salt Lake City, Utah, USA.
  2. Division of Rheumatology, and Lady Davis Research Institute, Jewish General Hospital, Quebec, Canada.

2015 Vol.33, N°4 ,Suppl.91
PI 0179, PF 0181
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 26339896 [PubMed]

Received: 02/04/2015
Accepted : 15/06/2015
In Press: 01/09/2015
Published: 01/09/2015


Systemic sclerosis (SSc, scleroderma) is characterised by complex multi-organ pathogenesis, including gastrointestinal tract (GIT) disease that remains poorly characterised. Immunosuppression is commonly used to treat inflammatory manifestations of SSc, including the skin, lungs and joints. There is a paucity of data on the effects of immunosuppression on GIT disease in SSc.
This case report and review of the literature presents two clinical cases in which interleukin-6 (IL-6) antagonism was used for early, diffuse skin disease.
In these two cases, IL-6 anta-gonism was associated with an exacerbation of GIT symptoms.
We postulate that IL-6 is important in the repair of GIT mucosa and further studies are warranted to better understand the effects of immunosuppression on SSc-GIT disease.

Rheumatology Article